Urological Research

, Volume 37, Issue 3, pp 147–152 | Cite as

Effects of specific α-1A/1D blocker on lower urinary tract symptoms due to double-J stent: a prospectively randomized study

  • Chung-Jing WangEmail author
  • Shi-Wei Huang
  • Chien-Hsing Chang
Original Paper


The aim of our study was to evaluate the effect of tamsulosin in improving symptoms in patients with indwelling double-J ureteral stents. This prospective study lasted from April 2006 to March 2008. All the patients with symptomatic lower ureteral stones with <15 mm diameter were enrolled, and were prospectively randomized (random numbers table) into two groups. A total of 154 patients, with insertion of a double-J ureteral stent after ureteroscopic stone removal. In group 1, 75 patients were enrolled and received placebo for 2 weeks. Group 2 included 79 patients who received 0.4 mg of tamsulosin, once daily for 2 weeks. All patients completed the validated ureteral stent symptom questionnaire (USSQ) and quality of life of international prostate symptom scale (IPSS) for evaluating the symptoms of double-J stents and quality of life after double-J stent insertion and removal, respectively. The analysis of the questionnaire at W1 revealed a significant difference in the main score index of urinary symptoms, body pain and general health between groups 1 and 2. When comparing W1 evaluation with that of W4 after double-J removal, both groups showed significant worsening of urinary symptoms, body pain, general health and work performance, except sexual performance. The mean score of quality of life in IPSS was 4.21 in group 1 and 1.6 in group 2. Tamsulosin can improve a subset of stent-related urinary symptoms and quality of life effectively and may be applied in routine clinical practice.


α-1A/1D blocker Double-J stent 


  1. 1.
    Zimskind PD, Fetter TR, Wilkerson JL (1967) Clinical use of long-term indwelling silicone rubber ureteral splints inserted cystoscopically. J Urol 97:840–844PubMedGoogle Scholar
  2. 2.
    Chew BH, Knudsen BE, Denstedt JD (2004) The use of stents in contemporary urology. Curr Opin Urol 14:111–115. doi: 10.1097/00042307-200403000-00011 PubMedCrossRefGoogle Scholar
  3. 3.
    Dyer RB, Chen MY, Zagoria RJ, Regan JD, Hood CG, Kavanagh PK (2002) Complications of ureteral stent placement. Radiographics 22:1005–1022PubMedGoogle Scholar
  4. 4.
    Lawrentschuk N, Russell JM (2004) Ureteric stenting 25 years on: routine or risky? ANZ J Surg 74:243–247. doi: 10.1111/j.1445-2197.2004.02947.x PubMedCrossRefGoogle Scholar
  5. 5.
    Joshi HB, Newns N, Stainthorpe A, MacDonagh RP, Keeley FX Jr (2003) Ureteral stent symptom questionnaire: development and validation of a multidimensional quality of life measure. J Urol 169:1060–1064. doi: 10.1097/01.ju.0000049198.53424.1d PubMedCrossRefGoogle Scholar
  6. 6.
    Deliveliotis C, Chrisofos M, Gougousis E, Papatsoris A, Dellis A, Varkarkis IM (2006) Is there a role for alpha1-blockers in treating double-J stent-related symptoms? Urology 67:35–39. doi: 10.1016/j.urology.2005.07.038 PubMedCrossRefGoogle Scholar
  7. 7.
    Richter S, Ringel A, Shalev M (2000) The indwelling ureteric stent: a “friendly” procedure with unfriendly high morbidity. BJU Int 85:408–411. doi: 10.1046/j.1464-410x.2000.00478.x PubMedCrossRefGoogle Scholar
  8. 8.
    Paz A, Amiel GE, Pick N, Moskovitz B, Nativ O, Potasman I (2005) Febrile complications following insertion of 100 double-J ureteral stents. J Endourol 19:147–150. doi: 10.1089/end.2005.19.147 PubMedCrossRefGoogle Scholar
  9. 9.
    Denstedt JD, Reid G, Sofer M (2000) Advances in ureteral stent technology. World J Urol 18:237–242. doi: 10.1007/PL00007074 PubMedCrossRefGoogle Scholar
  10. 10.
    Beiko DT, Knudsen BE, Denstedt JD (2003) Advances in ureteral stent design. J Endourol 17:195–199. doi: 10.1089/089277903765444294 PubMedCrossRefGoogle Scholar
  11. 11.
    Lingeman JE, Preminger GM, Berger Y, Denstedt J, Goldstone L, Segura J et al (2003) Use of a temporary ureteral drainage stent after uncomplicated ureteroscopy: results from a phase II clinical trial. Urology 169:1682–1688. doi: 10.1097/01.ju.0000055600.18515.a1 CrossRefGoogle Scholar
  12. 12.
    Kawabe K, Ueno A, Takimoto Y, Aso Y, Kato H (1990) Use of an alpha 1-blocker, YM617, in the treatment of benign prostatic hypertrophy. J Urol 144:908–912PubMedGoogle Scholar
  13. 13.
    Shibasaki M, Sudoh K, Inagaki O, Uchida W, Honda K (1992) Effect of the optical isomers of YM-12617 on increased intra-urethral pressure induced by phenylephrine in anaesthetized dogs. J Auton Pharmacol 12(4):263–268. doi: 10.1111/j.1474-8673.1992.tb00340.x PubMedCrossRefGoogle Scholar
  14. 14.
    Lepor H, Tang R, Shapito E (1993) The alpha-adrenoceptor subtype mediating the tension of human prostatic smooth muscle. Prostate 22:301–307. doi: 10.1002/pros.2990220404 PubMedCrossRefGoogle Scholar
  15. 15.
    Joshi HB, Stainthorpe A, MacDonagh RP, Keeley FX Jr, Timoney AG (2001) Indwelling ureteral stents: valuation of quality of life to aid outcome analysis. J Endourol 15:151–154. doi: 10.1089/089277901750134421 PubMedCrossRefGoogle Scholar
  16. 16.
    Joshi HB, Stainthorpe A, MacDonagh RP, Keeley FX Jr, Timoney AG (2003) Indwelling ureteral stents: evaluation of symptoms, quality of life and utility. J Urol 169:1065–1069. doi: 10.1097/01.ju.0000048980.33855.90 PubMedCrossRefGoogle Scholar
  17. 17.
    Kupeli B, Irkilata L, Gurocak S, Tunç L, Kiraç M, Karaoğlan Ü et al (2004) Does tamsulosin enhance lower ureteral stone clearance with or without shock wave lithotripsy? Urology 64:1111–1115. doi: 10.1016/j.urology.2004.07.020 PubMedCrossRefGoogle Scholar
  18. 18.
    Porpiglia F, Ghignone G, Fiori C, Fontana D, Scarpa R (2004) Nifedipine versus tamsulosin for the management of lower ureteral stones. J Urol 172:568–571. doi: 10.1097/01.ju.0000132390.61756.ff PubMedCrossRefGoogle Scholar
  19. 19.
    Davenport K, Timoney AG, Keeley FX Jr (2007) Effect of smooth muscle relaxant drugs on proximal human ureteric activity in vivo: a pilot study. Urol Res 35:207–213. doi: 10.1007/s00240-007-0100-x PubMedCrossRefGoogle Scholar
  20. 20.
    Hampel C, Gillitzer R, Pahernik S, Melchior SW, Thüroff JW (2005) Drug therapy of female urinary incontinence. Urologe 44:244–255. doi: 10.1007/s00120-005-0769-9 PubMedCrossRefGoogle Scholar
  21. 21.
    Serels S, Stein M (1998) Prospective study comparing hyoscyamine, doxazosin, and combination therapy for the treatment of urgency and frequency in women. Neurourol Urodyn 17:31–36. doi: 10.1002/(SICI)1520-6777(1998)17:1<31::AID-NAU6>3.0.CO;2-E PubMedCrossRefGoogle Scholar
  22. 22.
    Bregg K, Riehle RA Jr (1989) Morbidity associated with indwelling internal ureteral stents after shock wave lithotripsy. J Urol 141:510–512PubMedGoogle Scholar
  23. 23.
    Candela JV, Bellman GC (1997) Ureteral stents: impact of diameter and composition on patient symptoms. J Endourol 11:45–47PubMedCrossRefGoogle Scholar
  24. 24.
    Rane A, Saleemi A, Cahill D, Sriprasad S, Shrotri N, Tiptaft R (2001) Have stent-related symptoms anything to do with placement technique? J Endourol 15:741–745. doi: 10.1089/08927790152596352 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Chung-Jing Wang
    • 1
    Email author
  • Shi-Wei Huang
    • 1
  • Chien-Hsing Chang
    • 1
  1. 1.Division of Urology, Department of SurgerySaint Martin De Porres HospitalChiayiTaiwan, ROC

Personalised recommendations